Celtic Pharma Development Services

Quick facts

Phase 3 pipeline

• TDT067 · Autoimmune diseases
  TDT067 is a small molecule that targets the S1P1 receptor.
• Transfersome · Other

Phase 2 pipeline

• TA-NIC
• TDT067 and Lamisil

Phase 1 pipeline

• Xerecept 1.0
• Xerecept 2.0
• Xerecept 3.0

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Celtic Pharma Development Services portfolio CI brief
• Celtic Pharma Development Services pipeline updates RSS